Browsing Tag
ATH434
3 posts
Can Alterity Therapeutics’ penny stock (ASX: ATH) ride ATH434’s $2.4bn market potential to long-term gains?
Alterity Therapeutics eyes $2.4B peak sales for ATH434 in Multiple System Atrophy. Can this small-cap biotech turn clinical promise into commercial reality?
Alterity Therapeutics stock surges 33% after ATH434 momentum and FDA fast track designation
Alterity Therapeutics surged 33% after highlighting ATH434’s Phase 2 gains and FDA Fast Track status. Find out why investors are piling in now.
Alterity Therapeutics launches phase 2 trial of MSA candidate ATH434
Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in…